Atherosclerosis and Hyperlipidemia Research

Atherosclerosis is a disorder of the arteries characterized by the formation of hard structures called atherosclerotic plaques. It is a prevalent disorder, accounting for one third of all deaths in North America.

Atherosclerosis and Hyperlipidemia Research Products Targets

Products for Atherosclerosis and Hyperlipidemia Research - Page 9

Cat.No. Product Name Information/Activity
BCC7334 MK 571 MRP1 inhibitor; also CysLT<sub>1</sub> (LTD<sub>4</sub>) inverse agonist
BCC4680 Montelukast Sodium Montelukast (sodium) (MK0476) is a potent, selective CysLT1 receptor antagonist.
BCC4827 Pranlukast Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [3H]LTE4, [3H]LTD4, and [3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.
BCC7180 SR 2640 hydrochloride 146662-42-2
BCC6274 Gue 1654 397290-30-1
BCN2215 Arachidonic acid Arachidonic acid is an essential fatty acid and a major constituent of biomembranes.
BCC6038 BAY-X 1005 Veliflapon (BAY X 1005; DG-031) is an orally active and selective 5-lipoxygenase activating protein (FLAP) inhibitor. Veliflapon inhibits the synthesis of the leukotrienes B4 and C4.
BCC7457 Cilastatin sodium 81129-83-1
BCC7017 MK 886 MK886 is a potent 5-lipoxygenase activating protein inhibitor (FLAP) also a non-competitive inhibitor of PPAR alpha. a potent inhibitor of leukotriene (LT) biosynthesis in intact human polymorphonuclear leukocytes with IC 50 of 2.5 nM. Block the synthessis of leukotrien intact activate leukocyte.
BCC6717 17-ODYA Alkynyl Stearic Acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.